# Immune CHeckpoint Inhibitors Monitoring of Adverse Drug ReAction

> **NCT03492242** · — · COMPLETED · sponsor: **Groupe Hospitalier Pitie-Salpetriere** · enrollment: 1000 (actual)

## Conditions studied

- Arthritis
- Cancer
- Cardiac Disease
- Endocrine System Diseases
- Autoimmune Diseases
- Ophthalmopathy
- Myositis
- Neuropathy

## Interventions

- **DRUG:** Immune checkpoint inhibitor

## Key facts

- **NCT ID:** NCT03492242
- **Lead sponsor:** Groupe Hospitalier Pitie-Salpetriere
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-01
- **Primary completion:** 2018-09-30
- **Final completion:** 2018-09-30
- **Target enrollment:** 1000 (ACTUAL)
- **Last updated:** 2019-09-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03492242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03492242, "Immune CHeckpoint Inhibitors Monitoring of Adverse Drug ReAction". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03492242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*